US life expectancy vs. the world in 2025: Where do Americans stand?
But lurking beneath all these headlines and gripes lies a stubborn, unshakable fact: in 2025, Americans simply don't live as long as citizens in dozens of other high-income countries.
If you're an average American baby born this year, you're expected to live about 78 years. That sounds fine, maybe even good to some ears, but step outside US borders even just over to Canada or across the United Kingdom and it's abundantly clear: Americans are living shorter lives than almost all their economic peers and, frankly, than millions of people in less wealthy parts of the world.
So, what's going on? Let's take a look into what the latest data tells us about American longevity—and why, for all the tech innovations and world-class medical centers dotting the landscape, life expectancy here just keeps stagnating.
How does
US life expectancy
measure up?
First things first: life expectancy is the average number of years a newborn can expect to live under current mortality rates. In the US, that number hit a recent low after COVID-19 but has since bounced back a bit.
by Taboola
by Taboola
Sponsored Links
Sponsored Links
Promoted Links
Promoted Links
You May Like
American Investor Warren Buffett Recommends: 5 Books For Turning Your Life Around
Blinkist: Warren Buffett's Reading List
Undo
Still, it's not keeping pace with history—or with the rest of the developed world.
2023 US life expectancy: 78.4 years
Global Average (2025): 73.5 years
Ranking: 48th globally (and slipping)
Here's the kicker: the US is above the global average, but a few years below its 'peer' nations. Most of Western Europe, plus Japan, Australia, South Korea, and even some smaller nations like Monaco, enjoy life expectancies between 82 and 87 years.
Americans are on average living about 3–5 years less than their economic peers, and as much as 8 years less than the world leaders.
What the numbers really say
The Centers for Disease Control and Prevention (CDC) notes the latest stats for the US:
Both sexes: 78.4 years (2023 data)
Males: 75.8 years
Females: 81.1 years
By comparison, Canada, France, Japan, and even the UK all clock in well above the US average.
WHO (World Health Organization) data lines up: no matter which authority you check, the trend is the same.
America's rank in the longevity league
So where does that put the US? In 48th place (as per several reports) and, according to the latest forecasts by World Population Review, likely to drop even further down the list by 2050.
Other wealthy nations, meanwhile, continue to inch higher, sometimes gaining years while the US just creeps forward months at a time.
Peer nations growing faster: For example, Japan, Korea, Portugal, the UK, and Italy already clock in at 80+ years and counting.
US trend is stagnating: Some projections put the US at 80.4 years—in 2050. That's nearly a quarter-century just to gain a single year.
Why is the US lagging behind?
If you spent any time in a US health economics classroom, you might echo this refrain: Americans spend more—way more—on healthcare than anyone else, but live shorter lives.
Why?
Here's where things get sticky (and let's be real, infuriating). According to the CDC and public health research, several chronic and acute challenges conspire to keep US life expectancy low:
Cardiovascular disease and obesity: Rates here dwarf those in peer nations.
Diabetes: A chronic and costly epidemic.
"Diseases of despair": Suicide, alcoholism, and drug overdoses hit the US particularly hard.
Maternal and infant mortality: Above-average for a wealthy nation.
Motor vehicle fatalities: Still shockingly high.
Healthcare disparity: Insurance rates, cost barriers, and uneven healthcare access.
Socioeconomic inequality: Health outcomes dramatically vary by income, ZIP code, and racial group.
Americans are living shorter, sicker lives even as the country outspends rivals on everything from advanced surgeries to high-end drugs.
Comparing to the UK and peers: A stark gap
Let's pause and zero in on a particularly telling comparison: the United States vs.
the United Kingdom. Recent investigative reports by Johns Hopkins' Bloomberg School of Public Health deliver this sobering headline: Americans live years less than the Brits.
Leading causes of excess US deaths: Heart disease, drug overdoses, infant and maternal deaths
What really stands out isn't just the small year-by-year difference. It's the long-term trend: since the 1980s, America's trajectory has flatlined, while Europe trudges upward—even through its own crises.
Why?
Policy differences: Universal coverage, safety nets, and regenerative social programs in the UK and Europe often make healthier choices easier and provide fallback care when disaster strikes.
Public health investment: The UK spends less on care, but more on prevention and community wellness.
Digging into health habits and policy differences
If you're looking for 'silver bullet' explanations, the data won't cut you any slack. It's death by a thousand small problems, and they're entangled:
Diet: Appallingly high processed food consumption, sugar-sweetened beverages, and ultra-processed snacks.
Exercise: Sedentary lifestyles prevail, especially among kids and teens.
Addiction: A toxic brew of widespread opioid, meth, and alcohol abuse. Overdose rates have reached devastating levels.
Mental health: Underfunded and stigmatized, pushing more people into crisis and self-harm.
Healthcare Coverage: Insurance gaps, high out-of-pocket costs, and rural hospital closures remain endemic.
Environmental factors: Pockets of heavy pollution and 'food deserts.'
As the CDC points out, even American children today face a 1-in-5 shot at developing obesity before adulthood, foreshadowing future medical costs and mortality.
What would it take for America to catch up?
Public health experts and studies converge on a short list of must-dos:
Tackle chronic disease: Expand access to preventive screening, healthy foods, and physical activity.
Address the opioid crisis: Investment in mental health and addiction treatment.
Make healthcare universal and affordable: Reduce insurance and cost barriers.
Maternal and infant health: More prenatal care, family leave, and education.
Tackle poverty and inequality: Social safety nets, fair wages, and safer housing.
Without bolder national action—and strong local follow-through—these gains will remain elusive.
America's health gap is no longer a technical problem; it's a political, social, and moral one. Other countries have shown it's fixable, but it takes serious willpower and the humility to learn from others.
The question for the next generation, then, is simple: Will we keep coasting along on what's left of the old American advantage, or finally tackle the causes behind our shorter lives? For now, the world's watching and, to tell the truth, living longer.
References:
Johns Hopkins Bloomberg School of Public Health
CDC – Life Expectancy Data Briefs
WHO Data: United States
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
an hour ago
- Time of India
Install CCTV cameras in a week to curb misuse of scheduled drugs: Govt to medical shops
New Delhi: In a move to curb the sale of low-quality drugs and dual-use medicines without prescriptions, Delhi govt has directed all pharmaceutical and medical shops to install CCTV cameras on their premises by the end of July 2025. The order specifically targets high-risk drugs such as codeine-based cough syrups, alprazolam tablets and tramadol capsules, which are frequently misused—particularly by minors. In a letter addressed to Retail Distribution Chemist Alliance and other chemist associations across Delhi, special secretary (health and family welfare) Danish Ashraf stated: "Share this communication with all your members, conveying the directions not to indulge in the sale of Schedule H, H1, and X drugs without a valid prescription from a registered medical practitioner. Further, as per the deliberations held during the 11th NCORD meeting on July 18, your members/chemists are requested to install CCTV cameras at their premises by the end of July 2025. " These scheduled drugs are strictly regulated. Schedule H and H1 drugs cannot be sold over the counter and require a doctor's prescription. H1 drugs—such as strong antibiotics, anti-TB medicines, and habit-forming substances under the NDPS Act—require sales to be logged in a separate register. Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like They Were So Beautiful Before; Now Look At Them; Number 10 Will Shock You Reportingly Undo by Taboola by Taboola Schedule X drugs, such as barbiturates, amphetamines, and pentobarbital, are highly regulated, requiring special sale licences, secure storage under lock and key, and strict documentation, including prescription retention. You Can Also Check: Delhi AQI | Weather in Delhi | Bank Holidays in Delhi | Public Holidays in Delhi Officials added that the drug control department conducts regular inspections across the city to ensure compliance. It also carries out special drives from time to time to collect samples from retailers, wholesalers and institutions to check the quality of drugs available in the market. "In one such special drive conducted in June 2025, the department collected 127 samples of anti-cancer drugs from various outlets across the capital. Of these, 48 samples were tested and found to be genuine and compliant with prescribed quality norms. The results of the remaining 79 samples are awaited. All tested samples so far have been declared of standard quality," said KR Chawla, head of office, drug control department. The ongoing surveillance and quality checks aim to boost accountability and deter the over-the-counter sale of restricted drugs without medical supervision—while also ensuring that essential medicines, particularly for critical illnesses like cancer, meet safety and efficacy standards, said another official.
NDTV
an hour ago
- NDTV
COVID-19 May Trigger Alzheimer's-Like Protein Buildup In Brain And Eyes, Study Finds
New research suggests that COVID-19 can lead to protein build-up similar to that seen in Alzheimer's patients, not just in the brain but also in the eyes. Elevated amyloid beta levels were found in the retinal tissue of people who had COVID-19, similar to Alzheimer's-like retinal conditions. Notably, Amyloid beta buildup is associated with Alzheimer's disease. Researchers analysed two proteins, neuropilin-1 (NRP1) and angiotensin-converting enzyme 2 (ACE2). The NRP1 protein may serve as an entry point for viruses into human eyes and brains. Researchers found that introducing an NRP1 inhibitor countered the amyloid beta increase caused by COVID-19's spike protein. The study, led by Yale University and published in Science Advances, sheds light on COVID-19 brain fog, which was a commonly reported symptom following infection. The researchers believe that amyloid beta may act as a bodyguard for the brain, indicating underlying danger. "There is growing evidence linking COVID-19 and brain fog, a commonly reported symptom following infection," senior author Brian Hafler, ophthalmologist at Yale School of Medicine, said as quoted by Science Alert. "While the mechanisms of brain fog after COVID-19 are not fully understood, scientists have found that SARS-CoV-2 can induce amyloid beta accumulation in the central nervous system." The research team is conducting clinical studies to determine if COVID-19 increases the long-term risk of developing Alzheimer's disease, to explore NRP1 inhibitors as potential therapeutics. The involvement of NRP1 in amyloid beta aggregation provides a specific molecular target for future investigation. Other viruses may trigger similar amyloid beta buildups, as there's a need for further research. This study contributes to understanding the complex relationship between COVID-19 and neurological health. "Our study showed that exposure to SARS-CoV-2, in particular spike protein, can lead to the formation of amyloid beta aggregates in both human retinal tissue and retinal organoids," Hafler says.
Time of India
an hour ago
- Time of India
Rajendra Sonia turmeric sees huge surge in demand
1 2 3 4 Patna: A variety of turmeric, 'Rajendra Sonia', developed by Rajendra Prasad Central Agricultural University (RPCAU)-Pusa, is witnessing a huge surge in demand nationwide because of its high curcumin content. Significantly, this particular variety of turmeric contains a high curcumin content, ranging from 6% to 8.5%, making it a much sought-after commodity for its medicinal properties. Curcumin, a key component of turmeric, is known for its antioxidant, anti-inflammatory and anti-cancer properties. According to the agricultural scientists, its high concentration in 'Rajendra Sonia' makes it an attractive option for various applications, including pharmaceutical and food industries. RPCAU's vice-chancellor P S Pandey told this newspaper that the demand for 'Rajendra Sonia' turmeric is increasing across states, with many institutions and organisations seeking to cultivate it locally. The variety's high quality and certified curcumin content have contributed to its growing popularity. "The university's efforts to promote 'Rajendra Sonia' turmeric are expected to benefit the farmers significantly. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like AirSense 11 – Smart tech for deep sleep ResMed Buy Now Undo With the GI tagging of specific products, including Shahi litchi and Madhubani paintings, farmers can expect higher prices for their produce. For instance, the GI tagging of 'marcha dhan chura' from Motihari has already led to a significant increase in its price, benefiting local farmers," he said, adding that the university is working on identifying specific elements in various crop varieties to enhance their demand and value. RPCAU's scientist A K Mishra reported that the institution has sold over 347 quintals of 'Rajendra Sonia' turmeric seeds to institutions and organisations in several states, including Punjab, Haryana, Uttar Pradesh and Maharashtra. "The university has also distributed 130 quintals of Rajendra Sonia turmeric seeds to the farmers in the state, enabling them to cultivate and sell the crop at a higher price. This initiative is expected to boost the income of farmers and promote the cultivation of high-quality turmeric in the region," Mishra added.
